CA2768210C - 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt - Google Patents

9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt Download PDF

Info

Publication number
CA2768210C
CA2768210C CA2768210A CA2768210A CA2768210C CA 2768210 C CA2768210 C CA 2768210C CA 2768210 A CA2768210 A CA 2768210A CA 2768210 A CA2768210 A CA 2768210A CA 2768210 C CA2768210 C CA 2768210C
Authority
CA
Canada
Prior art keywords
salt
shows
batch
citrate
citrate salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2768210A
Other languages
English (en)
French (fr)
Other versions
CA2768210A1 (en
Inventor
Brian Dymock
Cheng Hsia Angeline Lee
Anthony Deodaunia William
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTI Biopharma Corp
Original Assignee
CTI Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CTI Biopharma Corp filed Critical CTI Biopharma Corp
Publication of CA2768210A1 publication Critical patent/CA2768210A1/en
Application granted granted Critical
Publication of CA2768210C publication Critical patent/CA2768210C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2768210A 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt Active CA2768210C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22560909P 2009-07-15 2009-07-15
US61/225,609 2009-07-15
PCT/SG2010/000265 WO2011008172A1 (en) 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Publications (2)

Publication Number Publication Date
CA2768210A1 CA2768210A1 (en) 2011-01-20
CA2768210C true CA2768210C (en) 2017-08-15

Family

ID=42790728

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2768210A Active CA2768210C (en) 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Country Status (18)

Country Link
US (1) US9062074B2 (https=)
EP (1) EP2454266B1 (https=)
JP (2) JP6013911B2 (https=)
CN (1) CN102762577B (https=)
AR (2) AR077483A1 (https=)
BR (1) BR112012000750B1 (https=)
CA (1) CA2768210C (https=)
DK (1) DK2454266T3 (https=)
ES (1) ES2429525T3 (https=)
HR (1) HRP20130941T1 (https=)
MX (1) MX2012000680A (https=)
PL (1) PL2454266T3 (https=)
PT (1) PT2454266E (https=)
RU (1) RU2543721C2 (https=)
SI (1) SI2454266T1 (https=)
SM (1) SMT201300112B (https=)
TW (1) TWI537276B (https=)
WO (1) WO2011008172A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
EP3389632A4 (en) 2015-12-15 2019-11-06 Context Biopharma Inc. AMORPHIC ONAPRISTON COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
WO2004078682A2 (en) * 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
NZ568325A (en) 2005-11-16 2011-05-27 S Bio Pte Ltd Macrocyclic oxygen linked pyrimidine derivatives

Also Published As

Publication number Publication date
CA2768210A1 (en) 2011-01-20
DK2454266T3 (da) 2013-09-08
EP2454266A1 (en) 2012-05-23
CN102762577A (zh) 2012-10-31
AR114987A2 (es) 2020-11-11
RU2012105044A (ru) 2013-08-20
BR112012000750B1 (pt) 2021-05-25
JP2015164941A (ja) 2015-09-17
TWI537276B (zh) 2016-06-11
JP2012533539A (ja) 2012-12-27
AR077483A1 (es) 2011-08-31
SMT201300112B (it) 2013-11-08
RU2543721C2 (ru) 2015-03-10
SI2454266T1 (sl) 2013-10-30
BR112012000750A2 (pt) 2016-08-09
ES2429525T3 (es) 2013-11-15
BR112012000750A8 (pt) 2018-02-06
US20120196876A1 (en) 2012-08-02
HRP20130941T1 (hr) 2013-11-08
CN102762577B (zh) 2015-01-07
JP6013911B2 (ja) 2016-10-25
WO2011008172A1 (en) 2011-01-20
EP2454266B1 (en) 2013-07-10
US9062074B2 (en) 2015-06-23
MX2012000680A (es) 2012-02-28
HK1178159A1 (en) 2013-09-06
PT2454266E (pt) 2013-10-10
TW201107336A (en) 2011-03-01
PL2454266T3 (pl) 2014-01-31

Similar Documents

Publication Publication Date Title
AU2014286047B2 (en) Crystalline forms of ponatinib hydrochloride
CA2768210C (en) 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt
US9624242B2 (en) 11-2(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
US8987243B2 (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt
HK1178159B (en) 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt
Sirikun et al. Solid-State Characterization and Interconversion of Recrystallized Amodiaquine Dihydrochloride in Aliphatic Monohydric Alcohols
WO2016004911A1 (en) A cocrystal of ivabradine hydrochloride and (r)-mandelic acid and its pharmaceutical composition
HK1161877B (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150702

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250520

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250520

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20251014

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251014

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260210